Citations

Showing 10 of 108119 citations.

Women’s Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review
Barrionuevo, Patricia , Castañeda-Guarderas, Ana, Zeballos‐Palacios, Claudia , Bora, Pavithra R., Mohammed, Khaled , Benkhadra, Khalid, Murad, M. Hassan , Gionfriddo, Michael R. , Zeballos-Palacios, Claudia, Bora, Pavithra, Sarigianni, Maria, Murad, Mohammad Hassan, Murad, M Hassan , Sarigianni, Maria

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 25, 2019 | Volume: 104 | Issue: 5 | Pages: 1631-1636

10.1210/jc.2019-00193 | PMID 30907968 Get It

Abstract Background Several treatments are available to reduce the risk of fragility fractures associated with osteoporosis. The choice of treatment requires knowledge of patients’ values and preferences. The aim of the present study was to summarize what is known about the values and preferences relevant to the management of osteoporosis in women. Methods We conducted a comprehensive search of several databases for studies reported in any language that had included women who had already started or were about to start any pharmacological therapy for osteoporosis. Pairs of reviewers independently selected the studies and extracted the data. The results were synthesized narratively. Results We included 26 studies reporting on 15,348 women (mean age, 66 years). The women considered the effectiveness and adverse events equally, followed by the convenience of taking the drug and its effect on daily routine (less frequent dosing was preferred, the oral route was preferred, and the injectable route was preferred over oral if given less frequently). The treatment cost and duration were less important factors for decision making. Fear of breast cancer and fear of resuming uterine bleeding were common reasons for not choosing estrogen therapy. Calcium and vitamin D were viewed as safe and natural. Across the studies, the preferences were not affected by age, previous drug exposure, or employment status. Conclusions Women starting osteoporosis medications value effectiveness and side effects equally and prefer medications given less frequently. Injectable drugs appear acceptable if given less frequently. More research on patient values and preferences is needed to guide decision making in osteoporosis.
Arthroscopic Evaluation of Knee Cartilage Using Optical Reflection Spectroscopy
Makovicka, Justin L. , Patel, Karan A. , Hartigan, David E. , Hassebrock, Jeffrey D. , Patel, Karan , Wong, Michael L. , Chhabra, Anikar

Mayo Clinic

Arthroscopy Techniques | March 25, 2019 | Volume: 8 | Issue: 4 | Pages: No page available

10.1016/j.eats.2018.11.019 | PMID 31110939 Get It

Abstract Articular cartilage is critical for painless and low‐friction range of motion; however, disruption of articular cartilage, particularly in the knee joint, is common. Treatment options are based on the size and depth of the chondral defect, as well as involvement of subchondral bone. The gold standard for evaluation of articular cartilage is with arthroscopy, but it is limited by its ability to objectively judge the depth and severity of chondral damage. Optical reflection spectroscopy has been introduced to objectively assess the thickness of cartilage. We present a technique to systematically evaluate the articular cartilage of the knee using BioOptico optical reflection spectroscopy (Arthrex) to better evaluate those with visible chondral and subchondral defects. Technique Video video See video under supplementary data.
Stress Management and Resilience Intervention in a Women's Heart Clinic: A Pilot Study
Bhagra, Anjali , Medina‐Inojosa, José R. , Vinnakota, Shravya , Arciniegas, Maria C., García, Mariana, Sood, Amit , Mahapatra, Saswati , Bauer, Brent A. , Cha, Stephen S., Medina-Inojosa, José R , Arciniegas, Maria, López-Jiménez, Francisco , Cha, Stephen S., Mulvagh, Sharon L.

Mayo Clinic

Journal of Women's Health | March 25, 2019 | Volume: 28 | Issue: 12 | Pages: 1705-1710

10.1089/jwh.2018.7216 | PMID 30907678 Get It

Background: In general, women report higher stress levels than men. High baseline anxiety, depression, and stress levels are associated with greater risk of cardiovascular diseases. Current evidence for efficacy of stress management interventions for women is limited. This study aimed at assessing the effect of a stress management and resiliency training (SMART) program for decreasing stress, anxiety, and depressive symptoms. Methods: Fifty moderately or severely stressed Women's Heart/Preventive Cardiology Clinic patients consented to the SMART intervention delivered online ( n = 36) or in-person ( n = 9). Primary outcome measures were the observed changes between baseline and at 12 weeks for the following psychometric tools: General Anxiety Disorder-7 (GAD-7), Patient Health Questionnaires (PHQ-9), Perceived Stress Scale (PSS), and Brief Resiliency Scale (BRS). Results: Forty-five patients completed the study. We observed significant improvements in PSS and GAD-7, but not in PHQ-9 or BRS, after the SMART intervention. When assessing outcomes among those with depressive symptoms at baseline (PHQ-9 > 15), we observed significant changes in PSS, GAD-7, and PHQ-9. No differences between online and in-person program delivery methods were found (all p -values >0.05). Conclusions: Training exposure using the SMART program to decrease stress and anxiety in women seeking preventive cardiology services was feasible and similarly effective, whether delivered online or in a single in-person session. Impacts on depression and resilience likely require a more intensive approach. In the future, larger randomized clinical trials with additional training and longer follow-up are warranted.
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Eastell, Richard , Rosen, Clifford J. , Black, Dennis M. , Cheung, Angela M. , Murad, M. Hassan , Shoback, Dolores , Rosen, Clifford J. , Murad, M Hassan , Cheung, Angela M

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 25, 2019 | Volume: 104 | Issue: 5 | Pages: 1595-1622

10.1210/jc.2019-00221 | PMID 30907953 Get It

Abstract Objective The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postmenopausal women. Conclusions Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for osteoporosis were critically evaluated in formulating this guideline for the management of postmenopausal osteoporosis. Patient preferences, data on adherence and persistence, and risks and benefits from the patient and provider perspectives were also considered in writing committee deliberations. A consensus by the Writing Committee members was achieved for four management principles: (i) The risk of future fractures in postmenopausal women should be determined using country-specific assessment tools to guide decision-making. (ii) Patient preferences should be incorporated into treatment planning. (iii) Nutritional and lifestyle interventions and fall prevention should accompany all pharmacologic regimens to reduce fracture risk. (iv) Multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk with acceptable risk-benefit and safety profiles.
5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway
Shinohara, Motoko, Shinohara, Mitsuru , Liu, Chia‐Chen , Kanekiyo, Takahisa , Bu, Guojun , Liu, Chia-Chen , Bu, Guojun , Zhao, Jing , Fu, Yuan

Mayo Clinic

International Journal of Molecular Sciences | March 25, 2019 | Volume: 20 | Issue: 6 | Pages: 1488

10.3390/ijms20061488 | PMID 30934555 Get It

Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentrations significantly increased apoE secretion from immortalized astrocytes and primary astrocytes derived from apoE3 and apoE4-targeted replacement mice without generating cellular toxicity. Other 5-HT3 antagonists also had similar effects as OS, though their effects were milder and required higher concentrations. Antagonists for other 5-HT receptors did not increase apoE secretion. OS also increased mRNA and protein levels of the ATB-binding cassette protein A1 (ABCA1), which is involved in lipidation and secretion of apoE. Accordingly, OS increased high molecular weight apoE. Moreover, the liver X receptor (LXR) and ABCA1 antagonists blocked the OS-induced increase of apoE secretion, indicating that the LXR-ABCA1 pathway is involved in the OS-mediated facilitation of apoE secretion from astrocytes. The effects of OS on apoE and ABCA1 were also observed in human astrocytes derived from induced pluripotent stem cells (iPSC) carrying the APOE ε3/ε3 and APOE ε4/ε4 genotypes. Oral administration of OS at clinically-relevant doses affected apoE levels in the liver, though the effects in the brain were not observed. Collectively, though further studies are needed to probe its effects in vivo, OS could be a potential therapeutic drug for AD by modulating poE metabolism through the LXR-ABCA1 pathway.
Targeting senescent cells alleviates obesity‐induced metabolic dysfunction
Xu, Ming , Zhu, Yi , Pirtskhalava, Tamar , Weivoda, Megan , Hachfeld, Christine, Prata, Larissa , Dijk, Theo H. van , Verkade, Esther, Casaclang‐Verzosa, Grace , Johnson, Kurt O. , Čubro, Hajrunisa, Doornebal, Ewald J. , Ogrodnik, Mikołaj , Jurk, Diana , Jensen, Michael D. , Chini, Eduardo N. , Miller, Jordan D. , Matveyenko, Aleksey V. , Schafer, Marissa , White, Thomas A. , Hickson, LaTonya J. , Demaria, Marco , Grande, Joseph P. , Kuipers, Folkert , Zglinicki, Thomas von , Campisi, Judith , Kirkland, James L. , Palmer, Allyson K. , Weivoda, Megan M, Hachfeld, Christine M, Prata, Larissa G, Casaclang-Verzosa, Grace, Matveyenko, Aleksey, Stout, Michael B, Schafer, Marissa J, Garovic, Vesna, Grande, Joseph, Hickson, LaTonya J , Xu, Ming , Jurk, Diana , Prata, Larissa G P Langhi , Schafer, Marissa J , Stout, Michael B , Garovic, Vesna D. , Arriaga, Edgar A. , LeBrasseur, Nathan K. , Tchkonia, Tamar , Zhu, Yi , Miller, Jordan

Mayo Clinic

Aging Cell | March 25, 2019 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/acel.12950 | PMID 30907060 Get It

Abstract Adipose tissue inflammation and dysfunction are associated with obesity‐related insulin resistance and diabetes, but mechanisms underlying this relationship are unclear. Although senescent cells accumulate in adipose tissue of obese humans and rodents, a direct pathogenic role for these cells in the development of diabetes remains to be demonstrated. Here, we show that reducing senescent cell burden in obese mice, either by activating drug‐inducible “suicide” genes driven by the p16 Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction. These senolytic interventions improved glucose tolerance, enhanced insulin sensitivity, lowered circulating inflammatory mediators, and promoted adipogenesis in obese mice. Elimination of senescent cells also prevented the migration of transplanted monocytes into intra‐abdominal adipose tissue and reduced the number of macrophages in this tissue. In addition, microalbuminuria, renal podocyte function, and cardiac diastolic function improved with senolytic therapy. Our results implicate cellular senescence as a causal factor in obesity‐related inflammation and metabolic derangements and show that emerging senolytic agents hold promise for treating obesity‐related metabolic dysfunction and its complications.
Classification of Subtypes of Apert Syndrome, Based on the Type of Vault Suture Synostosis
Lu, Xiaona , Sawh‐Martinez, Rajendra , Forte, Antonio J. , Wu, Robin T. , Cabrejo, Raysa, Wilson, Alexander T. , Steinbacher, Derek M., Alperovich, Michael , Alonso, Nivaldo , Persing, John A. , Jorge Forte, Antonio, Forte, Antonio Jorge

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | March 25, 2019 | Volume: 7 | Issue: 3 | Pages: e2158

10.1097/gox.0000000000002158 | PMID 31044122 Get It

Background: Apert syndrome patients are different in clinical pathology, including obstructive sleep apnea, cleft palate, and mental deficiency. These functional deficiencies may be due to anatomic deformities, which may be caused by different forms of associated suture fusion. Therefore, a classification system of Apert syndrome based on the type of craniosynostosis pattern might be helpful in determining treatment choices. Methods: CT scans of 31 unoperated Apert syndrome and 51 controls were included and subgrouped as: class I. Bilateral coronal synostosis; class II. Pansynostosis; and class III. Perpendicular combination synostosis: a. unilateral coronal and metopic synostosis; b. sagittal with bilateral/unilateral lambdoid synostosis; and c. others. Results: Class I is the most common (55%) subtype. The cranial base angulation of class I was normal; however, the cranial base angulation on the cranium side of the skull in class II increased 12.16 degrees (P = 0.006), whereas the facial side cranial base angle of class IIIa decreased 4.31 degrees (P = 0.035) over time. The external cranial base linear measurements of class I showed more evident reduction in anterior craniofacial structures than posterior, whereas other subtypes developed more severe shortening in the posterior aspects. Conclusions: Bicoronal synostosis is the most common subtype of Apert syndrome with the normalized cranial base angulation. Combined pansynostosis patients have flatter cranial base, whereas the combined unilateral coronal synostosis have a kyphotic cranial base. Class I has more significant nasopharyngeal airway compromise in a vertical direction, whereas classes II and III have more limited oropharyngeal space.
Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial
Guimarães, Patrícia O. , Lópes, Renato D. , Wojdyla, Daniel , Giczewska, Anna , Lewis, Basil S. , Hanna, Michael , Wallentin, Lars , Vinereanu, Dragoş , Alexander, John H. , Granger, Christopher B. , Hanna, Michael G. , Lopes, Renato D , Granger, Christopher B , Pokorney, Sean D. , Gersh, Bernard J. , Carnicelli, Anthony

Mayo Clinic

Clinical Cardiology | March 25, 2019 | Volume: 42 | Issue: 5 | Pages: 568-571

10.1002/clc.23178 | PMID 30907005 Get It

BackgroundThe optimal anticoagulation strategy for patients with atrial fibrillation (AF) and bioprosthetic valve (BPV) replacement or native valve repair remains uncertain.HypothesisWe evaluated the safety and efficacy of apixaban vs warfarin in patients with AF and a history of BPV replacement or native valve repair.MethodsUsing data from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) (n = 18 201), a randomized trial comparing apixaban with warfarin in patients with AF, we analyzed the subgroup of patients (n = 251) with prior valve surgery. We contacted sites by telephone to obtain additional data about prior valve surgery. Full data were available for 156 patients. The primary efficacy endpoint was stroke/systemic embolism. The primary safety endpoint was major bleeding. Treatment groups were compared using a Cox regression model.ResultsIn ARISTOTLE, 104 (0.6%) patients had a history of BPV replacement (n = 73 [aortic], n = 26 [mitral], n = 5 [mitral and aortic]) and 52 (0.3%) had a history of valve repair (n = 50 [mitral], n = 2 [aortic]). Among patients with BPVs, 55 were randomized to apixaban and 49 to warfarin. Among those with a history of native valve repair, 32 were randomized to apixaban and 20 to warfarin. Overall clinical event rates were low, with no significant differences between apixaban and warfarin for any outcomes.ConclusionsIn patients with AF and a history of BPV replacement or repair, the safety and efficacy of apixaban compared with warfarin was consistent with results from ARISTOTLE. These data suggest that apixaban may be reasonable for patients with BPVs or prior valve repair, though future larger randomized trials are needed.ClinicalTrials.govNCT00412984.
Comparison of In Situ Versus Subcutaneous Versus Submuscular Transpositions in the Management of McGowan Stage III Cubital Tunnel Syndrome
Izadpanah, Ali, Gibbs, Christopher M. , Spinner, Robert J. , Gibbs, Christopher, Kakar, Sanjeev

Mayo Clinic

HAND | March 25, 2019 | Volume: 16 | Issue: 1 | Pages: 45-49

10.1177/1558944719831387 | PMID 30907136 Get It

Background: The objective of the study was to evaluate and compare the clinical outcomes of in situ decompression with subcutaneous and submuscular transpositions for surgical management of advanced (McGowan stage III) cubital tunnel syndrome (CuTS). Methods: A retrospective review of patients in our institution undergoing primary surgery for CuTS from February 1989 to May 2009 was performed. Patients with advanced CuTS with a minimum of 12 months of follow-up without any previous bony or soft tissue procedures around the elbow were included. Seventy-four patients underwent 80 primary ulnar nerve surgeries. Patients’ demographics, presenting symptoms, physical examination, electrodiagnostic findings, and perioperative complications were recorded. Primary surgical techniques were compared and the risk factors for revision surgery were assessed. Results: Of the 80 surgical procedures, there were 17 decompressions (21%), 47 subcutaneous transpositions (59%), and 16 submuscular transpositions (20%). Fifty-two percent of patients had resolution of their symptoms after primary surgery. The overall complication rate after primary surgery was 12.5%. Nineteen patients (24%) had revision surgery at a median of 30 months after their primary procedure. Eight patients (42%) had symptomatic improvement after revision surgery. Patients with their dominant extremity affected, static 2-point discrimination (S2PD) greater than 10 mm, and age less than 50 years at presentation had a higher rate of revision surgery. Three patients had a second revision surgery and neurolysis for persistent symptoms. Conclusions: The overall revision rate in advanced CuTS was 24%. Forty-two percent of patients had reported subjective symptomatic improvement after revision surgery. Younger age at presentation and a greater S2PD were associated with a higher rate of revision surgery.